Comparative Pharmacology
Head-to-head clinical analysis: ECONAZOLE NITRATE versus KERYDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ECONAZOLE NITRATE versus KERYDIN.
ECONAZOLE NITRATE vs KERYDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Econazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking ergosterol synthesis, disrupting fungal cell membrane integrity and function.
KERYDIN (tavaborole) is a boron-based antifungal that inhibits fungal protein synthesis by blocking the activity of leucyl-tRNA synthetase, thereby preventing aminoacylation of tRNA(Leu) and impairing protein synthesis in dermatophytes.
Topical: Apply a thin layer to affected area twice daily (morning and evening). Vaginal: One applicatorful (150 mg) intravaginally at bedtime for 3 days. Rectal candidiasis: One 150 mg suppository rectally at bedtime for 3 days.
8 mg/kg (max 800 mg) IV over 2 hours once daily for 14 days
None Documented
None Documented
Terminal elimination half-life approximately 8-10 hours; clinical relevance: supports twice-daily topical dosing for sustained antifungal effect.
Terminal elimination half-life is approximately 24 hours, supporting once-daily topical application.
Primarily hepatic metabolism; <1% unchanged in urine; 30-45% in feces as metabolites; minimal biliary excretion.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 88% of the dose, with negligible fecal excretion (<1% as unchanged drug).
Category A/B
Category C
Antifungal
Antifungal